Rangeley Capital, LLC Esperion Therapeutics, Inc. Transaction History
Rangeley Capital, LLC
- $93.4 Billion
- Q1 2025
A detailed history of Rangeley Capital, LLC transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Rangeley Capital, LLC holds 92,500 shares of ESPR stock, worth $72,150. This represents 0.14% of its overall portfolio holdings.
Number of Shares
92,500
Previous 107,000
13.55%
Holding current value
$72,150
Previous $235 Million
43.42%
% of portfolio
0.14%
Previous 0.21%
Shares
2 transactions
Others Institutions Holding ESPR
# of Institutions
198Shares Held
119MCall Options Held
171KPut Options Held
679K-
Black Rock Inc. New York, NY14MShares$10.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.5MShares$8.96 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT10.9MShares$8.53 Million0.09% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.69MShares$7.56 Million0.32% of portfolio
-
Two Seas Capital LP Rye, NY6.93MShares$5.41 Million0.36% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $51.9M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...